FibroGen Inc (NASDAQ:FGEN) insider K Peony Yu sold 9,145 shares of the firm’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $56.30, for a total transaction of $514,863.50. Following the sale, the insider now owns 182,440 shares of the company’s stock, valued at approximately $10,271,372. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
FGEN opened at $56.50 on Friday. The company has a market capitalization of $4.83 billion, a P/E ratio of -54.85 and a beta of 1.74. FibroGen Inc has a 12 month low of $37.27 and a 12 month high of $68.55. The company has a quick ratio of 7.75, a current ratio of 7.75 and a debt-to-equity ratio of 0.18.
FibroGen (NASDAQ:FGEN) last released its quarterly earnings data on Wednesday, February 27th. The biopharmaceutical company reported $0.23 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.40. The company had revenue of $108.05 million during the quarter, compared to the consensus estimate of $72.15 million. FibroGen had a negative net margin of 40.58% and a negative return on equity of 16.84%. FibroGen’s revenue for the quarter was up 251.5% on a year-over-year basis. During the same period last year, the firm earned ($0.27) EPS. On average, equities analysts expect that FibroGen Inc will post -0.93 earnings per share for the current year.
Several brokerages have recently issued reports on FGEN. Zacks Investment Research lowered shares of FibroGen from a “buy” rating to a “hold” rating in a research note on Tuesday, March 12th. BidaskClub downgraded shares of FibroGen from a “buy” rating to a “hold” rating in a report on Wednesday, March 6th. ValuEngine downgraded shares of FibroGen from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 14th. Stifel Nicolaus started coverage on shares of FibroGen in a report on Monday, February 11th. They issued a “buy” rating and a $71.00 price objective for the company. Finally, Citigroup raised shares of FibroGen from a “neutral” rating to a “buy” rating and set a $71.00 price objective for the company in a report on Tuesday, December 18th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $72.40.
WARNING: “FibroGen Inc (FGEN) Insider Sells $514,863.50 in Stock” was posted by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://sportsperspectives.com/2019/03/17/fibrogen-inc-fgen-insider-sells-514863-50-in-stock.html.
FibroGen, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes therapeutic agents to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases (HIF-PHs) that is in Phase III clinical development for the treatment of anemia in chronic kidney disease; Pamrevlumab, a human-monoclonal antibody that inhibits the activity of connective tissue growth factor, which is in Phase II clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and Duchenne muscular dystrophy; and FG-5200, a corneal implant medical device for the treatment of corneal blindness resulting from partial thickness corneal damage.
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.